How many insider trades does FilingIQ track for ENSC?

FilingIQ tracks 14 Form 4 insider transactions for ENSC (Ensysce Biosciences, Inc.), covering filings from Jun 30, 2021 onwards. 1 of those were filed in the last 90 days.

Are ENSC insiders net buyers or net sellers?

Across the full Form 4 history for ENSC, 8 transactions (57%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ENSC insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ENSC in?

Ensysce Biosciences, Inc. (ENSC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.11M.

ENSC insider trading

NasdaqCM Healthcare

Ensysce Biosciences, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

57% / 0%

Market cap

$6.11M

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Company website: www.ensysce.com

ENSC insider activity at a glance

FilingIQ has scored 14 insider transactions for ENSC since Jun 30, 2021. The most recent filing in our index is dated Aug 7, 2026.

Across the full history, 8 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ENSC insider trades is 67.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ENSC trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 983

UNITED THERAPEUTICS Corp

NUVL 195

Nuvalent, Inc.

KYMR 193

Kymera Therapeutics, Inc.

GH 192

Guardant Health, Inc.

Hims & Hers Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for ENSC?: FilingIQ tracks 14 Form 4 insider transactions for ENSC (Ensysce Biosciences, Inc.), covering filings from Jun 30, 2021 onwards. 1 of those were filed in the last 90 days.
Are ENSC insiders net buyers or net sellers?: Across the full Form 4 history for ENSC, 8 transactions (57%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ENSC insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ENSC in?: Ensysce Biosciences, Inc. (ENSC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.11M.

Methodology & sources

Every ENSC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.